BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation

Learn more about:
Related Clinical Trial
Safety & Efficacy Study of Epcoritamab in Subjects With R/R Chronic Lymphocytic Leukemia and Richter’s Syndrome ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL Phase 1 Study VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome A Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Patients With Richter’s Syndrome; Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory NHL, RT, MM, T-PLL, Acute Leukemia (AML, ALL), MDS, MDS/MPN, and MF Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter’s Transformation Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma Venetoclax in Combination With Ublituximab and Umbralisib (TGR-1202) in Patients With Relapsed or Refractory CLL/SLL Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia Allogeneic Stem Cell Transplant for CLL Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin’s Lymphomas Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients With Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter’s Transformation Registry of the German CLL Study Group Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With Ofatumumab in Patients With Richter’s Syndrome PNT2258 for Treatment of Patients With Richter’s Transformation (Brighton) Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter’s Transformation Efficacy and Safety of Zanubrutinib Plus Tislelizumab for Treatment of Patients With Richter Transformation BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter’s Transformation and Leukemias Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter`s Transformation Requiring Allogeneic Stem Cell Transplantation Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS Study of Blinatumomab in Richter Transformation Genomic and Proteomic Study of Richter Syndrome (CGPSR) CRC043: A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R for Patients With Richter’s Syndrome Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter’s Transformation or Richter’s Syndrome Patients Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter’s Syndrome A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter’s Syndrome Selinexor in Initial or Refractory and/or Relapsed Richter’s Transformation

Brief Title

BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation

Official Title

BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation

Brief Summary

      Blinatumomab (BLINCYTO) is a bi-specific T-cell engaging (BiTE®) antibody construct that
      transiently links CD3-positive T cells to CD19-positive B-cells, inducing T-cell activation
      and subsequent lysis of tumor cells.

      The investigators propose to evaluate the efficacy, safety and tolerability of blinatumomab
      administered after R-CHOP debulking therapy in patients with Richter Syndrome (RS) of diffuse
      large B-cell lymphoma (DLBCL) histology.

      The investigators hypothesize that 8-week blinatumomab induction therapy leads to Complete
      Response (CR) rate improvement (revised Cheson criteria) from a baseline of 7percent as
      observed in the prospective study evaluating R-CHOP.
    


Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Complete remission (CR) rate according to the revised Lugano criteria

Secondary Outcome

 Number of patients with treatment-related adverse events as assessed by CTCAE v4.0

Condition

Richter Syndrome

Intervention

RCHOP

Study Arms / Comparison Groups

 R-CHOP- blinatumomab
Description:  Patients will first undergo a prior debulking therapy including 2 cycles of R-CHOP.
At Day1 (D1) : Rituximab 375 mg/m² Intravenous (IV) + Cyclophosphamide 750 mg/m² IV + Doxorubicin 50 mg/m² IV + Vincristine 1.4 mg/m² IV.
From D1 to D5 : Prednisone 60 mg/m² Per Os (PO). Patients with CR and no measurable lesion left will not be treated further in the setting of the present trial. All the remaining patients will be continuing and treating on study with a single cycle of blinatumomab induction therapy : Blinatumomab at 9 μg/d IV by continuous vein infusion from day 1-7, 28 μg/d from day 8-14 and 112 μg/d from day 15-56.
Patients who achieve an objective response after induction are eligible to receive one further optional cycle of blinatumomab consolidation : blinatumomab 9 μg/d IV by continuous vein infusion from day 1-7, 28 μg/d from day 8-14 and 112 μg/day IV from day 15-28.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

41

Start Date

July 5, 2019

Completion Date

July 4, 2022

Primary Completion Date

October 1, 2021

Eligibility Criteria

        Inclusion Criteria:

          -  Confirmed diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic
             lymphoma according to the revised iwCLL criteria19 with biopsy proven transformation
             to diffuse large B-cell lymphoma, consistent with RS according to the 2016 WHO
             classification

          -  Both patients with previously treated or treatment-naïve CLL are eligible

          -  Age greater than or equal to 18 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status <3

          -  Patients must meet the following hematologic criteria at screening, unless they have
             significant bone marrow involvement of either CLL or RS cells confirmed on biopsy:
             absolute neutrophil count ≥1.0 G/L, platelet count ≥50 G/L independent of transfusion
             within 7 days of screening

          -  Subject must have adequate coagulation, renal, and hepatic function at screening

          -  Adequate left ventricular ejection function (> 50 %)

          -  Patients who have undergone prior allogeneic hematopoietic stem-cell transplantation
             (HSCT) are eligible as long as they do not have significant active graft versus host
             disease and that their transplant day 0 is > 6 months from their first dose of
             protocol therapy

          -  Female patients of child bearing potential must have negative pregnancy test and use
             an effective method of birth control during treatment period and 48h thereafter; Males
             must use an effective method of birth control during treatment period and 48h
             thereafter.

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients with the Hodgkin variant of RS

          -  Patients with previously treated RS

          -  History or presence of clinically relevant disorder affecting the central nervous
             system (CNS)

          -  Known active DLBCL in the CNS (confirmed by cerebrospinal fluid analysis)

          -  Steroids treatment (≥ 20 mg for one week) before inclusion

          -  HSCT within 6 months before inclusion

          -  Active graft-versus-host disease

          -  History of other malignancies, except: i) malignancy treated with curative intent and
             with no recurrence over the last 5 years ii) adequately treated non-melanoma skin
             cancer without evidence of disease iii) adequately treated carcinoma in situ without
             evidence of disease

          -  History of human immunodeficiency virus

          -  Hepatitis B or C seropositivity (unless clearly due to vaccination)

          -  Pregnant or breastfeeding women

          -  Unwilling or unable to participate in all required study evaluations and procedures.

          -  Unable to understand the purpose and risks of the study and to provide a signed and
             dated informed consent form and authorization to use protected health information (in
             accordance with national and local subject privacy regulations)

          -  Abnormal screening laboratory values as defined as following: a) serum glutamate
             oxaloacetate transaminase and/or serum glutamate pyruvate transaminase and/or alkaline
             phosphatase > or =5 x upper limit of normal (ULN); b) Total bilirubin > or = 1.5 x
             ULN, unless due to Gilbert's disease; c) Creatinine > or = 2.0 x ULN or creatinine
             clearance <50 mL/min (calculated).

          -  Fertile male and female patients who cannot or do not wish to use an effective method
             of contraception during treatment and for 48h after the final treatment used for the
             purposes of the study

          -  Treatment with other investigational agent or participating to another trial within 30
             days prior to entering the study

          -  No affiliated to social security
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Romain GUIEZE, , 

Location Countries

France

Location Countries

France

Administrative Informations


NCT ID

NCT03931642

Organization ID

FILOCLL13-BLINART


Responsible Party

Sponsor

Study Sponsor

French Innovative Leukemia Organisation

Collaborators

 Amgen

Study Sponsor

Romain GUIEZE, Principal Investigator, University Hospital, Clermont-Ferrand


Verification Date

February 2022